Targeting RET for Thyroid Cancer Therapy: New Study Holds Promise

Strategic Insights -

A new study published in Biochemical Pharmacology has shed light on the potential of targeting the RET gene for thyroid cancer therapy. According to the study, activating mutations of the RET gene have been identified as driving oncogenic events in subsets of papillary and medullary thyroid carcinomas. The study's authors, C. Lanzi and colleagues, investigated the role of RET oncogenes and the encoded constitutively active oncoproteins as potential targets for therapy, highlighting the need for new therapeutic options in progressive thyroid carcinomas.

Key Takeaways:

  • The study highlights the need for new therapeutic options in progressive thyroid carcinomas, as conventional treatments have shown limited efficacy.
  • Activating mutations of the RET gene have been identified as driving oncogenic events in subsets of papillary and medullary thyroid carcinomas.
  • Targeted treatment for RET-driven cancers is not currently available in clinical therapy, but small molecule tyrosine kinase inhibitors are being evaluated in clinical trials for treatment of thyroid carcinomas.
  • Researchers have preclinically investigated the relevance of Ret oncoproteins as therapeutic targets for a subset of thyroid neoplastic diseases, identifying therapeutic opportunities for exploiting Ret inhibition.
  • The study's lead author, C. Lanzi, and colleagues published their findings in Biochemical Pharmacology, emphasizing the potential of targeting the RET gene for thyroid cancer therapy.

Statistics:

  • The study suggests that approximately 30% of papillary and medullary thyroid carcinomas are driven by activating mutations of the RET gene (Biochemical Pharmacology, 2009;77(3):297-309).
  • The multi-kinase inhibitors, including sorafenib, sunitinib, motesanib, and vandetanib, have shown efficacy against other neoplastic diseases, with the majority being antiangiogenic agents (Cancer Gene Therapy).
  • The preclinical evidence supports the relevance of Ret oncoproteins as therapeutic targets for a subset of thyroid neoplastic diseases (Biochemical Pharmacology, 2009;77(3):297-309).

Sources:

  • Lanzi, C., et al. (2009). Targeting RET for thyroid cancer therapy. Biochemical Pharmacology, 77(3), 297-309.
  • Cancer Gene Therapy (Source cited by Lanzi and colleagues)
  • Clinical Oncology Week editors (2009)